1. Please check and comment entries here.
Table of Contents

    Topic review

    Muscle-Invasive Bladder Cancer

    Subjects: Oncology
    View times: 5
    Submitted by: Anastasia Hepburn

    Definition

    Bladder cancer is the tenth commonest cancer worldwide. The occurrence of bladder cancer is a complex, multi-factor, multi-step pathological process, which has both internal genetic factors and external environmental factors.  Bladder cancer can be divided into non-muscle invasive bladder cancer and muscle invasive bladder cancer. Clinically, most patients with bladder cancer are in well-differentiated or moderately differentiated non-muscular invasive bladder cancer at the time of diagnosis (about 10% of them eventually develop into muscular invasive bladder cancer or metastatic bladder cancer) 

    1. Introduction

    Bladder cancer is the tenth commonest cancer worldwide with 549,000 new cases and 199,000 deaths reported in 2018 [1]. While 85% of patients present with less aggressive non-muscle invasive bladder cancer (NMIBC), they have a high risk of recurrence (50–70%) and up to 25% will progress to more advanced disease [2]. For patients that present with, or progress to, muscle invasive bladder cancer (MIBC), the mainstay of treatment is radical cystectomy and radiotherapy [3]. However, 5-year disease-free survival is as low as 15–35% and up to 50% of patients develop metastasis within two years of surgery inevitably succumbing to their disease [4]. Failure is usually due to occult micrometastatic disease present at diagnosis. Cisplatin-based neoadjuvant chemotherapy (NAC), including administering regimens such as MVAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin), is a promising strategy to achieve pathological downstaging as well as early eradication of micrometastasis to improve patient survival [3].
    High level evidence from two large, randomised trials and two meta-analyses demonstrated that the MVAC regimen prior to cystectomy resulted in a 5–10% increase in 5-year cancer-specific survival (CSS) in comparison to cystectomy alone [5][6][7][8]. Interestingly, the 5-year CSS for responders to NAC is 90% in contrast to 30–40% for non-responders. However, only approximately 40% of patients will have a major response to NAC (defined as absence of muscle-invasive disease and lymph node metastasis; <pT2 and pN0) and benefit from it. Furthermore, non-responders suffer substantial overtreatment, delay of surgery and loss of opportunity for further therapy due to physical deterioration from toxicity or to disease progression. Therefore, identification of a reliable method to stratify NAC administration based on predicted response is of critical importance for the management of MIBC patients and may ultimately lead to future personalised medicine. Recent studies have explored DNA repair gene mutations (ERCC1, ERCC2, BRCA1) [9][10][11][12], regulators of apoptosis (survivin, Bcl-xL) [13], receptor tyrosine kinase mutations (ERBB2) [14], gene expression signatures [13][15][16][17][18][19], molecular subtypes of bladder cancer [20][21][22][23] and alterations in the cellular mechanisms of drug uptake/transport (CTR-1, MDR1) [24][25] as potential predictors of response to NAC and offer promise for improving patient selection for such treatment and clinical outcomes. However, to date, no biomarker exists in the clinical setting to prospectively identify the patients most likely to benefit from NAC.

    2. CNGB1 as a Predictor of  Muscle-Invasive Bladder

    To date, there are no clinically approved biomarkers predictive of response to NAC and identification of such predictors remains crucial for the selection of the most effective treatment for MIBC patients. To address this clinical urgency, a mutli-methods analysis approach of differential gene expression and machine learning methods was undertaken on a cohort of MIBC patients highly selected for an exquisitely strong chemotherapeutic response or marked resistance and/or progression. This approach identified a 9-gene signature able to select responders from non-responders with 100% accuracy which further showed significant association with survival in our limited external validation and also highlighted CNGB1 as a promising potential biomarker to predict chemoresponsiveness of MIBC patients through validation in internal and external patient cohorts as well as in vitro studies.
    Multiple signatures predicting response to NAC have been reported previously in MIBC, identifying markers such as survivin, IPO7, TOP2A, PIR51, RACGAP1 and solute carriers such as SLC16A3 and SLC22A18 [13][15][16][17][18]. Even though none have been incorporated into routine clinical practice so far, they have provided positive steps towards achieving a precision medicine approach for the treatment of this disease. The interplay between bladder tumour biology, chemotherapy response and resistance mechanisms are complex. Recently, it has been suggested molecular subtyping may impact patient benefit to NAC [20][21][22][23]. Molecular subtypes have been discovered that are associated with specific clinicopathological characteristics and differential sensitivity to treatments. It will be interesting to interrogate expression of our signature and CNGB1 in these subtypes particularly those expected to be resistant to NAC, such as the p53-like expression subtype.
    Our analysis led to the identification of CNGB1, which encodes for one of the subunits that compose cyclic nucleotide-gated channels (CNGs). CNGs belong to the superfamily of voltage-gated ion channels and are key components for signal transduction by controlling the influx of cations, including Ca2+ ions, in response to signal-induced changes of cGMP or cAMP levels [26]. CNGs were first identified in retinal photoreceptors and olfactory sensory neurons, in which their function has been extensively studied [27][28]. Interestingly, Olfactory receptor 5P3 (OR5P3), a G-protein coupled-receptor also expressed by olfactory receptor neurons, was similarly upregulated in ‘non-responders’ and also identified in Signature 2 by RGIFE. CNGs expression has also been seen in other tissues including brain, liver and kidney, though their function in non-sensory cells is not as well understood [29]. Recently, a clinically aggressive variant of bladder cancer, sarcomatoid carcinoma, was shown to carry frequent mutations of CNGB1 [30]. CNGs form heterotetramers composed of up to three different types of subunits that determine the channel’s functional features, including CNGA1 which was also observed to be upregulated by ‘non-responders’ [31]. For example, rod photoreceptors comprise three CNGA1 subunit and one CNGB1 subunit, with the latter conferring Ca2+/Calmodulin-dependent modulation of channel activity. Upregulation of calcium-sensing proteins CALML3, CALML5 and S100A7A was also noted in ‘non-responders’. Previously, a correlation of S100A7A (also known as psoriasin) expression with poor bladder cancer survival was seen [32]. A role for other S100 family of calcium-binding proteins in bladder cancer cisplatin sensitivity has also been reported [33][34]. Interestingly, HIST1H4F, identified by both RGIFE and differential gene expression analysis, has been shown previously to be part of a prognostic signature [35].
    Calcium ions are one of the most important cellular messengers in biology and have been implicated many hallmarks of cancer [36]. Several drugs have been reported to block CNG channels including calcium channel blockers currently used in clinical practice in the management of high blood pressure, angina and cardiac arrhythmias, including dihydropyridines (e.g., nifedipine), phenylalkylamines (e.g., verapamil) and benzothiazepines (e.g., diltiazem) as well as the local anaesthetic tetracaine and calmodulin antagonists [27][37][38]. Calcium channel blockers can also enhance chemotherapy cytotoxicity by blocking the multidrug resistance protein P-glycoprotein, which through its function as an adenosine triphosphate-dependent drug efflux pump reduces intracellular chemotherapeutic drug accumulation [39].

    3. Conclusions

    We identified a novel gene signature able to select responders from non-responders with high predictive accuracy and highlighted CNGB1 as a simpler proxy as a promising potential biomarker to predict chemoresponsiveness of MIBC patients. Our signature gene set and the role of CNGB1 as a simpler proxy warrants additional larger scale validation in similar established cohorts of patients stratified based on response to NAC and ideally in trials of biomarker directed therapy in improving survival for MIBC patients.

    The entry is from 10.3390/cancers13153903

    References

    1. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424.
    2. Czerniak, B.; Dinney, C.; McConkey, D. Origins of Bladder Cancer. Annu. Rev. Pathol. 2016, 11, 149–174.
    3. Witjes, J.A.; Bruins, H.M.; Cathomas, R.; Compérat, E.M.; Cowan, N.C.; Gakis, G.; Hernández, V.; Espinós, E.L.; Lorch, A.; Neuzillet, Y.; et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur. Urol. 2020, 79, 82–104.
    4. Stein, J.P.; Lieskovsky, G.; Cote, R.; Groshen, S.; Feng, A.C.; Boyd, S.; Skinner, E.; Bochner, B.; Thangathurai, D.; Mikhail, M.; et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J. Clin. Oncol. 2001, 19, 666–675.
    5. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003, 361, 1927–1934.
    6. Vale, C.L. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 2005, 48, 202–205, discussion 205–206.
    7. Grossman, H.B.; Natale, R.B.; Tangen, C.M.; Speights, V.O.; Vogelzang, N.J.; Trump, D.L.; deVere White, R.W.; Sarosdy, M.F.; Wood, D.P., Jr.; Raghavan, D.; et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 2003, 349, 859–866.
    8. International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J. Clin. Oncol. 2011, 29, 2171–2177.
    9. Choueiri, T.K.; Jacobus, S.; Bellmunt, J.; Qu, A.; Appleman, L.J.; Tretter, C.; Bubley, G.J.; Stack, E.C.; Signoretti, S.; Walsh, M.; et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: Pathologic, radiologic, and biomarker correlates. J. Clin. Oncol. 2014, 32, 1889–1894.
    10. Font, A.; Taron, M.; Gago, J.L.; Costa, C.; Sánchez, J.J.; Carrato, C.; Mora, M.; Celiz, P.; Perez, L.; Rodríguez, D.; et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann. Oncol. 2011, 22, 139–144.
    11. Liu, D.; Plimack, E.R.; Hoffman-Censits, J.; Garraway, L.A.; Bellmunt, J.; Van Allen, E.; Rosenberg, J.E. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016, 2, 1094–1096.
    12. Van Allen, E.M.; Mouw, K.W.; Kim, P.; Iyer, G.; Wagle, N.; Al-Ahmadie, H.; Zhu, C.; Ostrovnaya, I.; Kryukov, G.V.; O’Connor, K.W.; et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014, 4, 1140–1153.
    13. Als, A.B.; Dyrskjøt, L.; von der Maase, H.; Koed, K.; Mansilla, F.; Toldbod, H.E.; Jensen, J.L.; Ulhøi, B.P.; Sengeløv, L.; Jensen, K.M.E.; et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 2007, 13 (15 Pt 1), 4407–4414.
    14. Groenendijk, F.H.; de Jong, J.; Fransen van de Putte, E.E.; Michaut, M.; Schlicker, A.; Peters, D.; Velds, A.; Nieuwland, M.; van den Heuvel, M.M.; Kerkhoven, R.M.; et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur. Urol. 2016, 69, 384–388.
    15. Kato, Y.; Zembutsu, H.; Takata, R.; Miya, F.; Tsunoda, T.; Obara, W.; Fujioka, T.; Nakamura, Y. Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling. Exp. Ther. Med. 2011, 2, 47–56.
    16. Takata, R.; Katagiri, T.; Kanehira, M.; Tsunoda, T.; Shuin, T.; Miki, T.; Namiki, M.; Kohri, K.; Matsushita, Y.; Fujioka, T.; et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 2005, 11, 2625–2636.
    17. Takata, R.; Katagiri, T.; Kanehira, M.; Shuin, T.; Miki, T.; Namiki, M.; Kohri, K.; Tsunoda, T.; Fujioka, T.; Nakamura, Y. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2007, 98, 113–117.
    18. Baras, A.S.; Gandhi, N.; Munari, E.; Faraj, S.; Shultz, L.; Marchionni, L.; Schoenberg, M.; Hahn, N.; Hoque, M.; Berman, D.; et al. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. PLoS ONE 2015, 10, e0131245.
    19. Williams, P.D.; Cheon, S.; Havaleshko, D.M.; Jeong, H.; Cheng, F.; Theodorescu, D.; Lee, J.K. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 2009, 69, 8302–8309.
    20. Choi, W.; Porten, S.; Kim, S.; Willis, D.; Plimack, E.R.; Hoffman-Censits, J.; Roth, B.; Cheng, T.; Tran, M.; Lee, I.-L.; et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014, 25, 152–165.
    21. McConkey, D.J.; Choi, W.; Shen, Y.; Lee, I.-L.; Porten, S.; Matin, S.F.; Kamat, A.M.; Corn, P.; Millikan, R.E.; Dinney, C.; et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur. Urol. 2016, 69, 855–862.
    22. Taber, A.; Christensen, E.; Lamy, P.; Nordentoft, I.; Prip, F.; Lindskrog, S.V.; Birkenkamp-Demtröder, K.; Okholm, T.L.H.; Knudsen, M.; Pedersen, J.S.; et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis. Nat. Commun. 2020, 11, 4858.
    23. Font, A.; Domènech, M.; Benítez, R.; Rava, M.; Marqués, M.; Ramírez, J.L.; Pineda, S.; Domínguez-Rodríguez, S.; Gago, J.L.; Badal, J.; et al. Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. Cancers 2020, 12, 1784.
    24. Kilari, D.; Iczkowski, K.A.; Pandya, C.; Robin, A.J.; Messing, E.M.; Guancial, E.; Kim, E.S. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients. Anticancer Res. 2016, 36, 495–501.
    25. Hoffmann, A.C.; Wild, P.; Leicht, C.; Bertz, S.; Danenberg, K.D.; Danenberg, P.V.; Stöhr, R.; Stöckle, M.; Lehmann, J.; Schuler, M.; et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010, 12, 628–636.
    26. Kaupp, U.B.; Seifert, R. Cyclic nucleotide-gated ion channels. Physiol. Rev. 2002, 82, 769–824.
    27. Nakamura, T.; Gold, G.H. A cyclic nucleotide-gated conductance in olfactory receptor cilia. Nature 1987, 325, 442–444.
    28. Chen, T.Y.; Peng, Y.-W.; Dhallan, R.S.; Ahamed, B.; Reed, R.R.; Yau, K.-W. A new subunit of the cyclic nucleotide-gated cation channel in retinal rods. Nature 1993, 362, 764–767.
    29. Richards, M.J.; Gordon, S.E. Cooperativity and cooperation in cyclic nucleotide-gated ion channels. Biochemistry 2000, 39, 14003–14011.
    30. Guo, C.C.; Majewski, T.; Zhang, L.; Yao, H.; Bondaruk, J.; Wang, Y.; Zhang, S.; Wang, Z.; Lee, J.G.; Lee, S.; et al. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019, 27, 1781–1793.e4.
    31. Trudeau, M.C.; Zagotta, W.N. Dynamics of Ca2+-calmodulin-dependent inhibition of rod cyclic nucleotide-gated channels measured by patch-clamp fluorometry. J. Gen. Physiol. 2004, 124, 211–223.
    32. Liu, J.; Zhao, Z.; Sun, Z.; Liu, C.; Cheng, X.; Ruge, F.; Yang, Y.; Jiang, W.G.; Ye, L. Increased expression of Psoriasin is correlated with poor prognosis of bladder transitional cell carcinoma by promoting invasion and proliferation. Oncol. Rep. 2020, 43, 562–570.
    33. Kim, W.T.; Kim, J.; Yan, C.; Jeong, P.; Choi, S.Y.; Lee, O.J.; Chae, Y.B.; Yun, S.J.; Lee, S.C.; Kim, W.J. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann. Oncol. 2014, 25, 974–979.
    34. Shiota, M.; Tsunoda, T.; Song, Y.; Yokomizo, A.; Tada, Y.; Oda, Y.; Naito, S. Enhanced S100 calcium-binding protein P expression sensitizes human bladder cancer cells to cisplatin. BJU Int. 2011, 107, 1148–1153.
    35. Sandoval, J.; Mendez-Gonzalez, J.; Nadal, E.; Chen, G.; Carmona, F.J.; Sayols, S.; Moran, S.; Heyn, H.; Vizoso, M.; Gomez, A.; et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 4140–4147.
    36. Izquierdo-Torres, E.; Hernández-Oliveras, A.; Fuentes-García, G.; Zarain-Herzberg, A. Calcium signaling and epigenetics: A key point to understand carcinogenesis. Cell Calcium 2020, 91, 102285.
    37. Duenas-Gonzalez, A.; García-López, P.; Herrera, L.A.; Medina-Franco, J.L.; González-Fierro, A.; Candelaria, M. The prince and the pauper. A tale of anticancer targeted agents. Mol. Cancer 2008, 7, 82.
    38. Brown, R.L.; Strassmaier, T.; Brady, J.D.; Karpen, J.W. The pharmacology of cyclic nucleotide-gated channels: Emerging from the darkness. Curr. Pharm. Des. 2006, 12, 3597–3613.
    39. El-Mahdy, H.A.; El-Husseiny, A.A.; Kandil, Y.I.; Gamal El-Din, A.M. Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein. Life Sci. 2020, 262, 118518.
    More